Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown
Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. At the 48-week mark, 84.5% of Tremfya patients in a phase 3 study achieved a score of 90 on the Psoriasis Area Severity Index (PASI), a commonly used metric for measuring… Read More »